Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

966
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
966
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.7K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.9K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Lipid Absorption01:24

Lipid Absorption

3.5K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

The emerging role of CETP inhibition in the prevention of Alzheimer's disease.

American journal of preventive cardiology·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026

Related Experiment Video

Updated: Apr 3, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K

Ezetimibe: a novel option for lowering cholesterol.

Michael H Davidson1

  • 1Chicago Center for Clinical Research, IL 60610-4324, USA. mdavidson@protocare.com

Expert Review of Cardiovascular Therapy
|March 20, 2004
PubMed
Summary
This summary is machine-generated.

High LDL-cholesterol increases heart disease risk. Ezetimibe, a cholesterol absorption inhibitor, effectively lowers LDL-cholesterol, especially when combined with statins, helping patients reach NCEP goals.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Related Experiment Videos

Last Updated: Apr 3, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Disorders

Background:

  • Elevated low-density lipoprotein (LDL)-cholesterol significantly increases coronary heart disease (CHD) risk.
  • Current National Cholesterol Education Program (NCEP) guidelines aim for LDL-cholesterol reduction for risk management.
  • Many high-risk patients fail to achieve therapeutic LDL-cholesterol goals with existing lipid-lowering therapies.

Purpose of the Study:

  • To evaluate the efficacy and safety of ezetimibe, a novel cholesterol absorption inhibitor.
  • To assess ezetimibe's effectiveness as monotherapy and in combination with statins.
  • To determine if ezetimibe facilitates achievement of NCEP LDL-cholesterol goals.

Main Methods:

  • Series of randomized, controlled, multicenter studies.
  • Ezetimibe administered as monotherapy and coadministered with various statins (simvastatin, atorvastatin, lovastatin, pravastatin).
  • Lipid parameters, including LDL-cholesterol, were monitored.

Main Results:

  • Ezetimibe monotherapy significantly improved LDL-cholesterol and other lipid levels with a placebo-comparable safety profile.
  • Coadministration with statins was more effective than statin monotherapy in lowering LDL-cholesterol and improving lipid profiles.
  • A greater proportion of patients achieved NCEP LDL-cholesterol goals when ezetimibe was added to statin therapy.

Conclusions:

  • Ezetimibe is an effective agent for lowering LDL-cholesterol and improving lipid profiles.
  • Ezetimibe, particularly in combination with statins, offers a valuable strategy for patients not meeting NCEP lipid goals.
  • The safety profile of ezetimibe plus statin therapy is comparable to statin monotherapy, supporting its broad clinical utility.